CH648848A5 - 1h-pyrrolo(2,1-c)(1,4)benzodiazepin-2-acrylsaeureamid-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. - Google Patents
1h-pyrrolo(2,1-c)(1,4)benzodiazepin-2-acrylsaeureamid-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. Download PDFInfo
- Publication number
- CH648848A5 CH648848A5 CH2187/80A CH218780A CH648848A5 CH 648848 A5 CH648848 A5 CH 648848A5 CH 2187/80 A CH2187/80 A CH 2187/80A CH 218780 A CH218780 A CH 218780A CH 648848 A5 CH648848 A5 CH 648848A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pyrrolo
- benzodiazepine
- general formula
- methyl
- acid amide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 15
- HGOZVUMJMGXJJB-UHFFFAOYSA-N 3-(7h-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)prop-2-enamide Chemical class C1=C2C=CC=CC2=NC=C2CC(C=CC(=O)N)=CN21 HGOZVUMJMGXJJB-UHFFFAOYSA-N 0.000 title claims 3
- 229940126601 medicinal product Drugs 0.000 title claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 11
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 11
- -1 alkaline earth metal salt Chemical class 0.000 claims description 10
- BIVATAPISXAMKP-UHFFFAOYSA-N 3-(1h-1,4-benzodiazepin-2-yl)prop-2-enamide Chemical class N1C(C=CC(=O)N)=CN=CC2=CC=CC=C21 BIVATAPISXAMKP-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- RMGVZKRVHHSUIM-UHFFFAOYSA-N dithionic acid Chemical compound OS(=O)(=O)S(O)(=O)=O RMGVZKRVHHSUIM-UHFFFAOYSA-N 0.000 claims description 6
- 239000012442 inert solvent Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 5
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 231100000419 toxicity Toxicity 0.000 claims description 4
- 230000001988 toxicity Effects 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 150000003464 sulfur compounds Chemical class 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 4
- 150000001768 cations Chemical group 0.000 claims 4
- 229910006080 SO2X Inorganic materials 0.000 claims 2
- 229910006127 SO3X Inorganic materials 0.000 claims 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- HLIVVJVYXWHXFW-UHFFFAOYSA-N 8-(3-amino-3-oxoprop-1-enyl)-7H-pyrrolo[2,1-c][1,4]benzodiazepine-7-sulfonic acid Chemical compound S(=O)(=O)(O)C1C(=CN2C1=CN=C1C(=C2)C=CC=C1)C=CC(=O)N HLIVVJVYXWHXFW-UHFFFAOYSA-N 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 241000187747 Streptomyces Species 0.000 claims 1
- 241000258975 Streptomyces refuineus subsp. thermotolerans Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 150000005560 carbamic acid amides Chemical class 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000626 sulfinic acid group Chemical group 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 238000000862 absorption spectrum Methods 0.000 description 12
- 239000011734 sodium Substances 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- PCJZRPDVONTWOJ-UHFFFAOYSA-N 3-(1,2-benzodiazepin-2-yl)prop-2-enamide Chemical compound NC(=O)C=CN1C=CC=C2C=CC=CC2=N1 PCJZRPDVONTWOJ-UHFFFAOYSA-N 0.000 description 5
- 102100040996 Cochlin Human genes 0.000 description 5
- 101000748988 Homo sapiens Cochlin Proteins 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229910006069 SO3H Inorganic materials 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CBSHRSXXAZQEGH-UHFFFAOYSA-M sodium 3-(1,2-benzodiazepin-2-yl)prop-2-enoylazanide Chemical compound [Na+].N=1N(C=CC=C2C=1C=CC=C2)C=CC(=O)[NH-] CBSHRSXXAZQEGH-UHFFFAOYSA-M 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 2
- 229940075931 sodium dithionate Drugs 0.000 description 2
- 150000003452 sulfinic acid derivatives Chemical class 0.000 description 2
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- OBAIHJABYRUGAP-UHFFFAOYSA-N 3-(diazepin-1-yl)prop-2-enamide Chemical compound NC(=O)C=CN1C=CC=CC=N1 OBAIHJABYRUGAP-UHFFFAOYSA-N 0.000 description 1
- NOOBJPMKZDQMDF-UHFFFAOYSA-N 8-(3-amino-3-oxoprop-1-enyl)-7h-pyrrolo[2,1-c][1,4]benzodiazepine-7-sulfinic acid Chemical compound C1=C2C=CC=CC2=NC=C2C(S(O)=O)C(C=CC(=O)N)=CN21 NOOBJPMKZDQMDF-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- HWYHDWGGACRVEH-UHFFFAOYSA-N n-methyl-n-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000000072 sodium resin Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8988679A JPS5615289A (en) | 1979-07-17 | 1979-07-17 | Novel benzodiazepinnbased compound 3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH648848A5 true CH648848A5 (de) | 1985-04-15 |
Family
ID=13983232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2187/80A CH648848A5 (de) | 1979-07-17 | 1980-03-20 | 1h-pyrrolo(2,1-c)(1,4)benzodiazepin-2-acrylsaeureamid-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4309437A (enExample) |
| JP (1) | JPS5615289A (enExample) |
| BE (1) | BE882305A (enExample) |
| CA (1) | CA1152985A (enExample) |
| CH (1) | CH648848A5 (enExample) |
| DE (1) | DE3010544C2 (enExample) |
| FR (1) | FR2461711A1 (enExample) |
| GB (1) | GB2053894B (enExample) |
| LU (1) | LU82272A1 (enExample) |
| NL (1) | NL8001531A (enExample) |
| SE (1) | SE436882B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1214774A (en) * | 1983-02-10 | 1986-12-02 | Yusei Shiraga | Benzodiazepine derivative |
| JPS59152329A (ja) * | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | 局所障害抑制剤 |
| JPS60168512U (ja) * | 1985-03-25 | 1985-11-08 | 株式会社栗田機械製作所 | 圧搾濾板の圧搾膜検査装置 |
| GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| GB9818730D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| GB9818732D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| PT1109812E (pt) * | 1998-08-27 | 2005-09-30 | Spirogen Ltd | Pirrolobenzodiazepinas |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| GB0226593D0 (en) * | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0321295D0 (en) * | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| GB0404578D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA2558195C (en) * | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| GB0404577D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP1723152B1 (en) * | 2004-03-09 | 2015-02-11 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| EP1879901B1 (en) * | 2005-04-21 | 2009-12-23 | Spirogen Limited | Pyrrolobenzodiazepines |
| GB0813432D0 (en) * | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP5870400B2 (ja) | 2010-04-15 | 2016-03-01 | シアトル ジェネティクス，インコーポレーテッド | 標的化ピロロベンゾジアゼピンコンジュゲート |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| SG11201400770SA (en) | 2011-09-20 | 2014-04-28 | Spirogen Sarl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| CN103998449A (zh) | 2011-10-14 | 2014-08-20 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓 |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
| EP2855481A1 (en) | 2012-04-30 | 2015-04-08 | UCL Business PLC | Pyrrolobenzodiazepines |
| EP2906296B1 (en) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| BR112015008251B1 (pt) | 2012-10-12 | 2023-09-26 | Medimmune Limited | Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados |
| ES2649990T3 (es) | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
| US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| NZ707486A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| ES2738310T3 (es) | 2012-10-12 | 2020-01-21 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3223854A1 (en) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3458069B1 (en) | 2016-05-18 | 2023-07-05 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| JP7049276B2 (ja) | 2016-06-24 | 2022-04-06 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピンおよびその結合体 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| EP3612537B1 (en) | 2017-04-18 | 2022-07-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| CN110536703B (zh) | 2017-04-20 | 2024-07-12 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
| UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
| RS62928B1 (sr) | 2017-08-18 | 2022-03-31 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| ES2967878T3 (es) | 2019-03-15 | 2024-05-06 | Medimmune Ltd | Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer |
| USD925487S1 (en) * | 2019-10-22 | 2021-07-20 | Lg Electronics Inc. | Audio player |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3523941A (en) * | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
| US3524849A (en) * | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
-
1979
- 1979-07-17 JP JP8988679A patent/JPS5615289A/ja active Granted
-
1980
- 1980-02-25 SE SE8001458A patent/SE436882B/sv not_active IP Right Cessation
- 1980-02-27 CA CA000346511A patent/CA1152985A/en not_active Expired
- 1980-03-04 US US06/127,984 patent/US4309437A/en not_active Expired - Lifetime
- 1980-03-10 GB GB8008033A patent/GB2053894B/en not_active Expired
- 1980-03-14 NL NL8001531A patent/NL8001531A/nl not_active Application Discontinuation
- 1980-03-19 FR FR8006153A patent/FR2461711A1/fr active Granted
- 1980-03-19 LU LU82272A patent/LU82272A1/fr unknown
- 1980-03-19 DE DE3010544A patent/DE3010544C2/de not_active Expired
- 1980-03-19 BE BE0/199851A patent/BE882305A/fr not_active IP Right Cessation
- 1980-03-20 CH CH2187/80A patent/CH648848A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2053894B (en) | 1983-04-20 |
| US4309437A (en) | 1982-01-05 |
| FR2461711A1 (fr) | 1981-02-06 |
| CA1152985A (en) | 1983-08-30 |
| LU82272A1 (fr) | 1980-07-01 |
| NL8001531A (nl) | 1981-01-20 |
| BE882305A (fr) | 1980-07-16 |
| JPS6237631B2 (enExample) | 1987-08-13 |
| DE3010544C2 (de) | 1982-07-01 |
| GB2053894A (en) | 1981-02-11 |
| SE436882B (sv) | 1985-01-28 |
| JPS5615289A (en) | 1981-02-14 |
| FR2461711B1 (enExample) | 1983-05-13 |
| SE8001458L (sv) | 1981-01-18 |
| DE3010544A1 (de) | 1981-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3010544C2 (de) | 1H-Pyrrolo[2,1-c][1,4]benzodiazepin-2-acrylsäureamid-Verbindungen und ihre Verwendung bei der Bekämpfung maligner Neoplasien | |
| CH637398A5 (de) | Verfahren zur herstellung von maytansinoidverbindungen. | |
| DE2911248A1 (de) | Herstellung von maytansinoiden und maytansinoide | |
| AT394725B (de) | Verfahren zur herstellung von neuen mitomycin-c-analogen | |
| DE60125958T2 (de) | Reagenzien zur bestimmung von atomaren sauerstoff | |
| CH634567A5 (de) | Verfahren zur herstellung von uracilderivaten. | |
| DE3413489C2 (enExample) | ||
| DE2149750A1 (de) | Erythromycin-Derivate | |
| DE3730748A1 (de) | Neue polyoxygenierte labdanderivate, ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| DE3132221A1 (de) | Neue cyclophosphamid-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE68914223T2 (de) | Mitomycinderivate. | |
| CH644608A5 (de) | Verfahren zur herstellung von penicillansaeure-1,1-dioxid und dessen estern sowie zwischenverbindungen zur durchfuehrung des verfahrens. | |
| DE3241764A1 (de) | Neue azino-rifamycine | |
| EP0043967A1 (de) | 2,9-Dioxatricyclo(4,3,1,0(3,7))decane | |
| AT349481B (de) | Verfahren zur herstellung von neuen morpholinderivaten, ihren n-oxiden und salzen | |
| DD202163A5 (de) | Verfahren und zwischenstufen zur herstellung von 1,1-dixopenicillanoyloxymethyl-6 (2-amino-2-phenylacetamido)penicillanaten | |
| CH454129A (de) | Verfahren zur Herstellung von Dibenzo-dihydrocycloheptenen | |
| DE69011747T2 (de) | Beta-lactam-Elastase-Inhibitoren. | |
| CH646176A5 (de) | Beta-lactam-antibiotika mit beta-lactamase-hemmwirkung. | |
| DE2501861C2 (de) | 3,4,6-Tri-O-acyl-2-desoxy-2-nicotinoylamino-1-O-nicotinoyl-&beta;-D-glucopyranosen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate | |
| EP0080061B1 (de) | Neue cis-Bicyclo(3.3.0)octanderivate, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen und Arzneimittel | |
| DE1931097C3 (de) | Verfahren zur Herstellung von 6-Isocyana to- penicillansäure derivaten | |
| DE2808006A1 (de) | Verfahren zur herstellung von prostacyclin und seinen analogen | |
| DE2723417C3 (de) | 5,6-Epineamin und dessen Verwendung bei der Bekämpfung bakterieller Infektionen | |
| DE2534515A1 (de) | Neue zwischenprodukte zur synthese von beta-lactamderivaten und verfahren zu deren herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |